ArticleBMC neurology2022
Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?
Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Determinants of survival after re-resection for recurrent glioblastoma: a meta-analysis.Acta neurochirurgica · 2026Pooled it
- Charlson comorbidity Index for descriptive risk stratification of long-term All-cause mortality in elderly patients with acute myocardial infarction: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Development of a Prognostic Nomogram Model and Establishment of a Risk Stratification System Based on the Naples Prognostic Score for Patients with Oropharyngeal Squamous Cell Carcinoma Who Have Undergone Radical Surgery.Journal of inflammation research · 2026Article
- Medical comorbidities prognosticate survival in glioblastoma.BJC reports · 2025Article
- Beyond Molecular Characterization: The Impact of Age-Adjusted Charlson Comorbidity Index in Glioblastoma Patients Treated with Radio or Radio-Chemotherapy.Journal of clinical medicine · 2025Article
- Von Hippel-Lindau/Hypoxia Inducible Factor Axis in Glioblastoma.International journal of molecular sciences · 2025Review
- Comorbidity burden in elderly high-grade glioma patients: impact on radiotherapy outcomes.BMC cancer · 2025Article
- Optimizing Prediction of In-Hospital Mortality in Elderly Patients With Acute Myocardial Infarction: A Nomogram Approach Using the Age-Adjusted Charlson Comorbidity Index Score.Journal of the American Heart Association · 2024Article
- Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model.Journal of neuro-oncology · 2024Article
- Clinical Features of Actinomycosis in Older Adults: A 10-Year Experience of a Single Institute in Beijing, China.Cureus · 2024Article
- Glioblastoma and Internal Carotid Artery Calcium Score: A Possible Novel Prognostic Partnership?Journal of clinical medicine · 2024Article
- The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy.International journal of general medicine · 2024Article
- Brain metastases in the elderly - Impact of residual tumor volume on overall survival.Frontiers in oncology · 2023Article
- Predictive Value of the Geriatric Trauma Outcome Score in Older Patients After Trauma: A Retrospective Cohort Study.International journal of general medicine · 2022Article
- Can Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Outcomes of Patients With Recurrent Glioblastoma?In vivo (Athens, Greece)Article
- Real-world mortality and the effect of comorbidities on survival in glioblastoma: A database study using computed phenotypes for rapid, reliable patient identification.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor recurrent glioblastoma (GB) patients, several therapy options have been established over the last years such as more aggressive surgery, re-irradiation or chemotherapy. Age and the Karnofsky Performance Status Scale (KPSS) are used to make decisions for these patients as these are established as prognostic factors in the initial diagnosis of GB. This study's aim was to evaluate preoperative patient comorbidities by using the age-adjusted Charlson Comorbidity Index (ACCI) as a prognostic factor for recurrent GB patients.
methodsIn this retrospective analysis we could include 123 patients with surgery for primary recurrence of GB from January 2007 until December 2016 (43 females, 80 males, mean age 57 years (range 21-80 years)). Preoperative age, sex, ACCI, KPSS and adjuvant treatment regimes were recorded for each patient. Extent of resection (EOR) was recorded as a complete/incomplete resection of the contrast-enhancing tumor part.
resultsMedian overall survival (OS) was 9.0 months (95% CI 7.1-10.9 months) after first re-resection. Preoperative KPSS > 80% (P < 0.001) and EOR (P = 0.013) were associated with significantly improved survival in univariate analysis. Including these factors in multivariate analysis, preoperative KPSS < 80 (HR 2.002 [95% CI: 1.246-3.216], P = 0.004) and EOR are the only significant prognostic factor (HR 1.611 [95% CI: 1.036-2.505], P = 0.034). ACCI was not shown as a prognostic factor in univariate and multivariate analyses.
conclusionFor patients with surgery for recurrent glioblastoma, the ACCI does not add further information about patient's prognosis besides the well-established KPSS and extent of resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.